ProMIS Neurosciences 과거 수익 실적

과거 기준 확인 0/6

ProMIS Neurosciences의 수입은 연평균 -18.1%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 7.7%의 비율로 증가했습니다. 매출은 연평균 70.7%의 비율로 감소해 왔습니다.

주요 정보

-18.1%

수익 성장률

2.5%

EPS 성장률

Biotechs 산업 성장	-14.6%
매출 성장률	-70.7%
자기자본 수익률	-7.7%
순이익	n/a
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

ProMIS Neurosciences 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

DB:23J0 수익, 비용 및 수입 (USD Millions )
날짜	수익	G+A 비용	R&D 비용
30 Sep 24	-1	6	0
30 Jun 24	-12	4	0
31 Mar 24	-12	6	0
31 Dec 23	-13	6	0
30 Sep 23	-17	6	0
30 Jun 23	-20	8	0
31 Mar 23	-21	5	0
31 Dec 22	-18	6	0
30 Sep 22	-13	6	0
30 Jun 22	-8	6	0
31 Mar 22	-6	5	0
31 Dec 21	-10	4	0
30 Sep 21	-8	2	0
30 Jun 21	-8	1	0
31 Mar 21	-9	2	0
31 Dec 20	-4	2	0
30 Sep 20	-5	2	0
30 Jun 20	-5	2	0
31 Mar 20	-5	2	0
31 Dec 19	-6	2	0
30 Sep 19	-7	2	0
30 Jun 19	-8	2	0
31 Mar 19	-8	2	0
31 Dec 18	-7	2	0
30 Sep 18	-6	2	0
30 Jun 18	-5	2	0
31 Mar 18	-5	2	0
31 Dec 17	-5	2	0
30 Sep 17	-5	2	0
30 Jun 17	-4	2	0
31 Mar 17	-3	1	0
31 Dec 16	-3	1	0
30 Sep 16	-2	1	0
30 Jun 16	-2	1	0
31 Mar 16	-2	1	0
31 Dec 15	-2	1	0
30 Sep 15	-1	1	0
30 Jun 15	-2	1	0
31 Mar 15	-2	1	0
31 Dec 14	-2	1	0
30 Sep 14	-3	1	0
30 Jun 14	-2	1	0
31 Mar 14	-2	1	0
31 Dec 13	-2	1	-1

양질의 수익: 23J0 은(는) 현재 수익성이 없습니다.

이익 마진 증가: 23J0 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 23J0 은(는) 수익성이 없으며 지난 5년 동안 연간 18.1% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 23J0 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: 23J0 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -18.2% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: 23J0 현재 수익성이 없기 때문에 마이너스 자본 수익률( -7.75% )을 갖습니다.

ProMIS Neurosciences 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First half earnings released

Recent updates

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences, Inc. Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences, Inc. announced that it expects to receive CAD 30.3 million in funding from Great Point Partners, LLC, Armistice Capital LLC, Ally Bridge Group, Sphera Funds Management Ltd and other investors

ProMIS Neurosciences, Inc. Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Receives Written Notice from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5550(b)(2)

ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease

ProMIS Neurosciences to Delist from TSX

ProMIS Neurosciences Inc. Announces FDA Clearance of Investigational New Drug Application for PMN310 in Alzheimer’s Disease

No longer forecast to breakeven

ProMIS Neurosciences, Inc. announced that it has received $7.472277 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. to Present At 2022 Alzheimer's Association International Conference

ProMIS Neurosciences Common Shares Deleted from Other OTC

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Pmn310 Antibody Demonstrates Significant Cognitive Benefit in A Mouse Model of Alzheimer’s Disease

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. Initiates Program to Develop Monoclonal Antibodies to Treat Schizophrenia and Other Chronic Mental Illnesses

ProMIS Neurosciences, Inc. has completed a Composite Units Offering in the amount of $17.5 million.

ProMIS Neurosciences, Inc. Initiates Commercialization of Covid-19 Serology Assay

ProMIS Neurosciences Re-Initiates Path to IND for PMM310 with Producer Cell Line Development

ProMIS Neurosciences, Inc. announced that it has received CAD 8.75 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences, Inc. Announces Perspectives on Recent Progress in the Alzheimer's Field

Revenue in line with expectations

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

ProMIS Neurosciences, Inc. Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

ProMIS Neurosciences, Inc. Announces Resignation of Anthony Giovinazzo from the Board of Directors

ProMIS Neurosciences, Inc. to Develop Multivalent Vaccine for Alzheimer’s Disease

First half earnings released

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기